Biotech Values

[biomaven0]

>Aragon

It's in Phase II:

http://clinicaltrials.gov/ct2/show/study/NCT01171898?term=NCT01171898&rank=1

The drug itself is a somewhat more potent than MDV3100, but quite unclear if that would correspond with any sort of clinical benefit given that MDV3100 is very well tolerated. Also seems likely to me from what I've read about the licensing deal that Medivation would be found to have rights to this drug if it ever were to go anywhere.

Peter